Protein–protein interactions (PPI) were once considered 'undruggable', but clinical
successes, driven by advanced methods in drug discovery, have challenged that notion …

Protein-protein interactions (PPIs) are well-established as a class of promising drug targets
for their implications in a wide range of biological processes. However, drug development …

SIRT6, a member of the SIRT deacetylase family, is responsible for deacetylation of histone
H3 N ε-acetyl-lysines 9 (H3K9ac) and 56 (H3K56ac). As a tumor suppressor, SIRT6 has …

The adenomatous polyposis coli (APC) gene plays a pivotal role in the pathogenesis of
colorectal carcinoma (CRC) but remains a challenge for drug development. Long noncoding …

Based on the high frequency of concurrent adenomatous polyposis coli (APC) and KRAS
mutations and their strong cooperative interaction in human colorectal cancer (CRC) …

Development of fluorescence polarization (FP) assays, especially in a competitive manner,
is a potent and mature tool for measuring the binding affinities of small molecules. This …

Bioactive peptides are actively involved in different biological functions and importantly
contribute to human health, and the use of peptides as therapeutics has a long successful …

Traditionally, drugs are monovalent, targeting only one site on the protein surface. This
includes orthosteric and allosteric drugs, which bind the protein at orthosteric and allosteric …

Protein‐protein interactions (PPIs) are closely implicated in various types of cellular activities
and are thus pivotal to health and disease states. Given their fundamental roles in a wide …

Highlights•Hidden allosteric sites provide valuable avenues for allosteric drug
discovery.•Hidden allosteric sites are invisible in the ligand-unbound crystal structures.• …